血清CYFRA21-1联合NSE检测在非小细胞肺癌患者中的表达及临床意义  

Expression and Clinical Significance of Serum CYFRA21-1 Combined with NSE Detection in Non-small Cell Lung Cancer Patients

作　　者：董树晓 Dong Shuxiao(Department of Clinical Laboratory,General Hospital of Jinshui District Zhengzhou City,Zhengzhou,Henan,450000,China)

机构地区：[1]郑州市金水区总医院医学检验科,河南郑州450000

出　　处：《黑龙江医学》2025年第5期596-599,共4页Heilongjiang Medical Journal

摘　　要：目的:探讨血清细胞角蛋白19片段抗原21-1(CYFRA21-1)联合神经元特异性烯醇化酶(NSE)检测在非小细胞肺癌患者中的表达及临床意义。方法:前瞻性选取2022年1—12月郑州市金水区总医院就诊的60例非小细胞肺癌患者作为研究对象。所有患者入院后均接受6个周期的化疗,通过实体瘤疗效评价标准评估疗效,发放调查问卷了解并记录患者人口学资料,同时整理患者病理情况,于患者入院时、化疗结束检测CYFRA21-1、NSE水平表达,根据疗效判断预后并分组,重点分析CYFRA21-1、NSE水平在非小细胞肺癌患者中的表达与意义。结果:经过化疗,非小细胞肺癌患者整体的CYFRA21-1、NSE水平均较入院时有所降低,差异均有统计学意义(t=14.832、10.712,P<0.05);不同性别、年龄、体质量指数(BMI)和患者入院时的CYFRA21-1、NSE水平对比,差异无统计学意义(t=0.643,F=0.039、0.186;P>0.05),不同肿瘤分期、分化程度、直径、转移情况患者入院时CYFRA21-1、NSE水平比较,差异均有统计学意义(t=2.076、2.042、2.026、4.568、6.777,F=3.965;P<0.05);化疗周期结束,全部60例患者,预后良好22例,占比36.67%;预后不良38例,占比63.33%;相较于预后良好组,预后不良组入院时CYFRA21-1、NSE水平较高,差异有统计学意义(t=4.568、6.777,P<0.05);经logistic回归分析结果显示,非小细胞肺癌患者入院时CYFRA21-1、NSE水平与化疗预后有一定关系,二者异常过表达可能是预后不良的影响因素(OR>1,P<0.05)。结论:CYFRA21-1、NSE水平在非小细胞肺癌患者中呈异常过表达,尤其是在不同肿瘤分期、分化程度、直径、转移患者中异常表达较为明显,且这种异常表达可能对化疗预后有一定影响,联合检测二者水平表达或可评估预后风险,指导早期治疗。Objective:To explore the expression and clinical significance of serum CYFRA21-1 combined with NSE detection in non-small cell lung cancer patients.Methods:A prospective selection was conducted on 60 patients with non-small cell lung cancer who visited the General Hospital of Jinshui District,Zhengzhou City from January to December 2022.All patients received 6 cycles of chemotherapy after admission.The efficacy was evaluated by solid tumor efficacy evaluation criteria.Questionnaires were issued to understand and record the demographic data of the patients.At the same time,the pathological conditions of the patients were sorted out.The expression of CYFRA21-1 and NSEwas detected at the time of admission and at the end of chemotherapy.The prognosis was judged and grouped according to the efficacy.The expression and significance of CYFRA21-1 and NSE levels in patients with non-small cell lung cancer were analyzed.Results:After chemotherapy,the overall levels of CYFRA21-1 and NSE in non-small cell lung cancer patients decreased compared to those at admission(t=14.832,10.712;P<0.05).There was no statistically significant difference in CYFRA21-1 and NSE levels at admission in patients with different gender,age and body mass index(t=0.643,F=0.039,0.186;P>0.05).There were statistically significant differences in CYFRA21-1 and NSE levels at admission in patients with different tumor stage,degree of differentiation,diameter and metastasis(t=2.076,2.042,2.026,4.568,6.777;F=3.965;P<0.05).At the end of the chemotherapy cycle,of all 60 patients,22 had a good prognosis,accounting for 36.67%.38 cases had poor prognosis,accounting for 63.33%.Compared with good prognosis group,the poor prognosis group had higher levels of CYFRA21-1 and NSE at admission(t=4.568、6.777,P<0.05).The results of logistic regression analysis showed that there was certain relationship between the levels of CYFRA21-1 and NSE at admission and chemotherapy prognosis in non-small cell lung cancer patients.Abnormal overexpression of the two may be a contribut

关 键 词：非小细胞肺癌 细胞角蛋白19片段抗原21-1 神经元特异性烯醇化酶 表达 

分 类 号：R331.1[医药卫生—人体生理学]